🧬 What Bristol Myers Squibb Does
Bristol Myers Squibb (NYSE: BMY) is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative prescription medicines. Its research focuses on oncology, hematology, immunology, cardiovascular disease, and neuroscience, with long-term growth driven by scientific innovation, product launches, and pipeline development.
💡 Plain English: Bristol Myers Squibb generates revenue from patented medicines and continually develops new therapies to replace products that eventually lose patent protection.
📊 Financial Highlights
- Total revenue remained stable at approximately $48.2 billion in FY2025.
- Net income recovered to $7.1 billion after a loss in FY2024 as acquisition-related expenses declined.
- Operating cash flow remained strong at approximately $14.2 billion.
- The company reduced long-term debt while maintaining more than $10 billion in cash and cash equivalents.
💡 Plain English: Sales stayed relatively steady, profitability recovered, and Bristol Myers Squibb continued generating strong cash despite ongoing investment in future growth.
⚠️ Key Risks
- Patent expirations and competition from generic and biosimilar medicines.
- Clinical trial failures and regulatory approval uncertainty.
- Government pricing reforms and reimbursement pressure.
- Manufacturing quality, supply chain, and product safety risks.
- Intellectual property litigation and cybersecurity threats.
💡 Plain English: Bristol Myers Squibb’s long-term success depends on protecting its patents, developing new medicines, and successfully bringing those medicines to market.
📈 MD&A Highlights
Management stated that FY2025 represented a year of operational normalization. Revenue remained stable while lower acquisition-related expenses allowed earnings to recover. The company continued investing heavily in research and development, expanding its Growth Portfolio, advancing late-stage pipeline programs, reducing debt, and maintaining strong cash generation to support future innovation.
💡 Plain English: Management’s priority is to replace aging blockbuster medicines with newer products while maintaining financial flexibility through strong cash flow.
🎯 Takeaway
Bristol Myers Squibb’s FY2025 10-K shows a company navigating a portfolio transition rather than pursuing rapid revenue growth. Stable sales, improving profitability, strong operating cash flow, and continued investment in the product pipeline demonstrate management’s focus on building the next generation of innovative medicines while managing future patent expirations.
💰 Income Statement Summary
| (Unit: $m, EPS in $) | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Revenue | 45,006 | 48,300 | 48,194 |
| Cost of Goods Sold | 10,693 | 13,968 | 13,936 |
| Gross Profit | 34,313 | 34,332 | 34,258 |
| SG&A | 7,772 | 8,414 | 7,267 |
| Operating Income | 7,282 | (7,486) | 10,002 |
| Non-Operating Income/Expense | 2,324 | 1,054 | 1,217 |
| Interest Income/Expense | (1,166) | (1,947) | (1,891) |
| Income Before Tax | 8,440 | (8,379) | 9,328 |
| Income Tax | 400 | 554 | 2,272 |
| Net Income | 8,025 | (8,948) | 7,054 |
| EPS | 3.9 | (4.4) | 3.5 |
Plain English: Bristol Myers Squibb’s revenue was essentially flat in FY 2025, moving from $48,300m in FY 2024 to $48,194m. The bigger story was profitability. FY 2024 showed a large operating loss because acquisition-related research expenses and amortization were unusually high. In FY 2025, those costs declined sharply, allowing operating income to recover to $10,002m and net income to return to $7,054m. For beginner investors, this means BMS did not mainly recover because sales exploded; it recovered because major expense pressure eased.
📈 Key Financial Ratios
| Ratio | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| ROE (%) | 27.2% | (54.6%) | 40.7% |
| ROA (%) | 8.4% | (9.7%) | 7.8% |
| ROTC (%) | 7.7% | (8.1%) | 11.1% |
| ROIC (%) | 7.8% | (7.4%) | 9.0% |
| Gross Margin (%) | 76.2% | 71.1% | 71.1% |
| Operating Margin (%) | 16.2% | (15.5%) | 20.8% |
| Pretax Margin (%) | 18.8% | (17.3%) | 19.4% |
| Net Margin (%) | 17.8% | (18.5%) | 14.6% |
| Debt-to-Equity Ratio (D/E) (%) | 135.1% | 303.0% | 243.8% |
| Net Debt / EBITDA (x) | 1.5x | 2.0x | 1.8x |
| Interest Coverage Ratio (x) | 6.2x | (3.8x) | 5.3x |
| Current Ratio (%) | 142.7% | 125.3% | 125.5% |
| Quick Ratio (%) | 130.7% | 114.5% | 114.0% |
| Fixed Asset to Long-term Capital Ratio (%) | 18.2% | 28.0% | 27.8% |
Plain English: Bristol Myers Squibb’s profitability ratios improved significantly in FY 2025 after a difficult FY 2024. Operating Margin increased from (15.5%) to 20.8%, showing that the core business became profitable again as acquisition-related expenses declined. ROE and ROIC also rebounded, indicating stronger returns generated from shareholders’ capital and invested capital.
Although Debt-to-Equity remained relatively high at 243.8%, leverage improved compared with FY 2024 as Bristol Myers Squibb repaid a portion of its long-term debt and rebuilt shareholders’ equity. Liquidity also remained healthy, with both the Current Ratio and Quick Ratio staying comfortably above 100%, suggesting the company has sufficient short-term assets to meet near-term obligations.
For beginner investors, the most important takeaway is that FY 2024 should be viewed as an unusual year driven by acquisition-related accounting charges rather than a collapse of the underlying business. The recovery across nearly every profitability ratio in FY 2025 suggests the company’s core operating performance remained resilient while continuing to generate strong cash flows.
📝 Disclaimer
This article is intended for educational purposes only. It does not constitute financial, investment, or legal advice. All investment decisions involve risks, and readers should conduct their own research or consult with a licensed financial advisor.
👉 Bristol Myers Squibb (BMY) FY 2025 10-K Analysis (Filed 2026) | Explained for Beginners
Originally published on Finvincio